Leif Hakansson MD, PhD

Leif Hakansson is CEO & Head of Research. Leif Håkansson has a background as Associate Professor at the University of Lund, Sweden, and Consultant in Oncology and Head of the Division of Clinical Tumor Immunology at the University Hospital in Linköping, Sweden.

He received both his MD and PhD at the University of Lund, and has since held various positions at both the University of Lund and the University Hospital in Linkoping.

Dr Hakansson's research include immune parameters of importance for response, monitoring and optimization of immunotherapy and biochemotherapy in various types of cancer, e.g. renal cell carcinoma, malignant melanoma and colorectal cancer. He has published more than 75 peer-reviewed articles, given approximately 40 congress presentations on these and other topics and holds several patents on methods for the prediction and monitoring of immunotherapy of cancer.